Abstract
Introduction Spain has been disproportionately affected by the COVID-19 pandemic, ranking fifth in the world in terms of both total cases and total deaths due to COVID-19 as of May 20, 2020. Here we derived estimates of pandemic severity and assessed its relationship with socio-demographic and healthcare factors.
Methods We retrieved the daily cumulative numbers of laboratory-confirmed COVID-19 cases and deaths in Spain from February 20, 2020 to May 20, 2020. We used statistical methods to estimate the time-delay adjusted case fatality risk (aCFR) for 17 autonomous communities and 2 autonomous cities of Spain. We then assessed how transmission and sociodemographic variables were associated with the aCFR across areas using multivariate regression analysis.
Results We estimated the highest aCFR for Madrid (25.9%) and the average aCFR in Spain (18.2%). Our multivariate regression analysis revealed three statistically significant predictor variables: population size, population density, and the unemployment rate.
Conclusions The estimated aCFR for 10 autonomous communities/cities in Spain are significantly higher than those previously estimated for other geographic regions including China and Korea. Our results suggest that public health interventions focused on densely populated areas and low socioeconomic groups can ameliorate the mortality burden of the COVID-19 pandemic in Spain.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KM acknowledges support from the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 20H03940, and from the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture, Sport, Science & Technology of Japan.
GC acknowledges support from NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program; UK Biotechnology and Biological Sciences Research Council grant BB/M008894/1.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first authors
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
